Zymeworks halts development of cancer drug after trial setback

ReutersSep 2, 2025 10:06 AM

Sept 2 (Reuters) - Zymeworks ZYME.O said on Tuesday it will stop developing its experimental cancer drug after early-stage trial results showed the treatment was unlikely to meet the company's goals as a standalone therapy.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Semiconductor Sector Continues to Rise, Should Retail Investors Buy Intel or AMD?

TradingKey - On April 23 (ET), Intel released its latest quarterly earnings report, which showed revenue grew 7% to $13.6 billion and earnings per share (EPS) reached $0.29, beating expectations. Analysts had previously forecast average revenue of $12.4 billion and EPS of $0.01.

SAP First-Quarter Cloud Revenue Grows 27% Year-on-Year; After-Hours ADRs Once Rise Over 10%

TradingKey - SAP SE released its Q1 2026 financial results. During the period, under International Financial Reporting Standards (IFRS), the group's total revenue was €9.555 billion, up 6% year-on-year, largely in line with market expectations. Net profit attributable to the parent company was €1.932 billion, a 9% increase year-on-year. Diluted earnings per share (EPS) was €1.65, compared to €1.51 in the same period last year, representing a 9% year-on-year increase.

Intel Better-Than-Expected Earnings Released, Stock Surges 20% After-Hours, AI Computing Power Enters CPU Moment?

TradingKey - Driven by the global boom in AI infrastructure construction, demand for server chips is seeing explosive growth. Intel (INTC), which fell behind in the early stages of the AI race, is accelerating its recovery on the back of better-than-expected earnings.

Today’s Market Recap: Iran Tensions Stir Market, U.S. Stocks Dip as Intel Soars 20% in After-Hours Trading

TradingKey - On April 23, 2026, Thursday, the S&P 500 declined by 0.42% to 7,108, while the Nasdaq Composite fell 0.89% to close at 24,439.

Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

TradingKey - On April 23, Intel (INTC.US) shares rose as much as 2% in pre-market trading before paring gains. This follows an announcement by Tesla CEO Elon Musk that Tesla will use Intel's advanced 14A manufacturing process to produce AI chips for its Terafab project, making Tesla the first major customer for Intel's 14A technology.

Featured Tools